Gilead Sciences

• Truvada, manufactured by Gilead Sciences, was the first drug to be approved by FDA for use as PrEP. It is a single pill which is the combination of ARVs tenofovir and emtricitabine.
• In October 2019, FDA has approved another medication by California based Gilead Sciences, Descovy, designed to prevent people from becoming infected with HIV.
• Facing harsh criticism over the prices of the drug, Truvada, Gilead Sciences announced in May that it would release its patent on the drug next year.

Teva Pharmaceuticals

• The company entered into an agreement with Gilead Sciences to launch generic versions of Truvada and Atripla by 2020.

Mylan

• Mylan Pharmaceuticals produce the genetic version of PrEP/HIV drug, Ricovir EM, which can be bought for as little as one-tenth the cost of Gilead’s Truvada.
• However, this generic drug has not been approved by FDA for U.S markets.

Drivers of the Industry

• Cost is a focus point for the consumers of PrEP drugs and fewer than 200,000 of the 1.2 million eligible Americans are enrolled in a PrEP program due to financial burden. Hence, generic drugs with their cost-effectiveness has huge global market potential.
• Promotion of PrEP/HIV drugs as demedicalised service by the brands, which means being offered in the same way that condoms, lubricant are, in a non-medical context will help in creating more awareness and encouraging people to adopt this safe and effective method of prevention.

Proprietary Research

• In addition to this public search, we scanned our proprietary research database of over 1 million sources and were unable to find any specific research reports that address your goals.